A-ADAM, a new EU-funded project developing test systems for Alzheimer’s disease

Age-related neurodegenerative disorders represent a considerable medical and economic challenge for the health care sector. However, drug development for neurodegenerative disorders is severely hampered by a lack of predictive test systems in the preclinical phase.

To address this need, the EUREKA-Eurostars initiative of the European Union approved a project grant to E-PHY-SCIENCE in Valbonne, France, CeGaT GmbH in Tübingen, Germany and the NMI at the University of Tübingen. The project aims at the development of novel drug test systems for Alzheimer’s disease. A new animal model, an in vitro test system and a new diagnostic test will be generated by combining an established genetic animal model for Alzheimer’s disease with another animal model for age-dependent mitochondrial impairment.

The partners expect a considerable improvement over current drug test systems for age-dependent neurodegeneration which will speed up the validation of novel treatments.

http://www.e-phy-science.com/

http://www.nmi.de/en/

Sequencing services expanded to include transcriptome sequencing

CeGaT has expanded our sequencing services to include transcriptome sequencing, also known as transcriptomics. This method is valuable for both basic and clinical research.
Using transcriptome sequencing, the whole RNA content of a biological sample can be detected and quantified. It is helpful for the following objectives:

  • Analysis of differential gene expression
  • Detection of alternative splicing
  • Detection of novel transcripts

The protocol can be adapted to the desired application and the sample limitations. For example, the low-input protocol needs only 1 ng RNA or 200 cells for the analysis to be performed.

For further information regarding transcriptome sequencing, please visit the transcriptome analysis section.

For the official launch of this service, we offer transcriptome sequencing at a special price of EUR 3.990 for 3 groups with 3 biological replicates and respective bioinformatics analysis (VAT not included) until the end of October 2015*.
* when receiving RNA (min. 1 µg RNA, RIN>8), the sequencing mode is 1x 50 bp, with an average output of 30 M/sample, and a processing time of 6-8 weeks

Expansion of available sequencing services by research exomes

CeGaT has expanded its product range in the field of sequencing services by offering exome analyses for research purposes.

The service includes exome sequencing and, if required, also comprehensive data analysis. Thereby, the sequencing depth can be adjusted to the specific demand. Customers from research areas are given the opportunity to receive an analysis fitting to their requirements and may also profit from the quality already established in our diagnostics.

Further advantages:

  • Possibility to adjust the protocol depending on the quality and amount of received sample material.
  • In case of receiving samples from several family members pedigrees and inheritance models may be considered.
  • When receiving tumor tissue together with corresponding normal tissue we are able to perform a comparative analysis of tumor vs. normal tissue for the targeted identification of somatic mutations.

Please visit the section Research: Exome for further information.

For the official launch of this service we offer the exome at a special price of EUR 800 (VAT not included) until the end of September 2015*.

* When receiving DNA, sequencing depth 10-12 GB, maximum of 20 exomes per customer

New study finds high risk for breast cancer in carriers of PALB2 mutations

A study recently published in the New England Journal of Medicine shows a highly increased risk to develop breast cancer for carriers of pathogenic mutations in PALB2 gene. Antoniou et al. determined a ninefold increase in breast cancer risk for both genders.

CeGaT offers the analysis of PALB2 and other risk genes via its panel for breast and ovarian cancer (CAN02).

You can find more information about the study on the website of the New England Journal of Medicine.

CeGaT participates in pancreatic cancer research

CeGaT GmbH has joined a scientific research consortium of leading European scientists to identify the genetic causes of pancreatic cancer. The European Union FP7-Programm, which will last five years, is publicly funded with over 11 million euros. Eleven partners from five countries are working together for a better understanding of this extremely aggressive and difficult-to-treat cancer. Prof. Dr. Thomas Gress, University hospital Marburg, and PD Dr. Malte Buchholz, University of Marburg, have initiated and are coordinating the joint efforts of physicians, molecular biologists, computer specialists, and small to medium companies.

The central goal of CAM-PaC is the development of pancreatic cancer computer models that will be used to identify new therapeutic targets and molecules. CeGaT is contributing to the consortium by providing its expertise in transcriptomic profiling and interpretation. The first step is the establishment of routine protocols for quantitative interpretation of transcriptomes of clonal-sphere-cultures (CSC) that assemble approximately 40 – 100 individual cells. For interpretation of the obtained results, CeGaT will closely interact and develop new algorithms together with the group of PD Dr. Hans Kestler, University of Ulm.